One Saint Mary Place
Shreveport, LA 71101-4343
Delta Pathology Molecular Diagnostics
Welcome to DeltaMDx.com
Delta MDx is a branch of Delta Pathology Group, L.L.C that delivers clinical molecular and cytogenetics testing services for many hospitals and surgery centers throughout Louisiana, East Texas, and South Arkansas. Our services are under the medical direction of pathologists and the laboratory is Certified by the College of American Pathologists.
mission critical testing for the region
An integral part of the Delta Pathology Group
We strive to provide comprehensive, state of the art, reliable and accurate diagnostic molecular pathology and cytogenetic services to assist in the management of oncologic and non-oncologic diseases. We emphasize a multidisciplinary approach to cancer diagnosis by having close interaction with oncologists, surgeons, radiologists, radiation oncologists, medical sub-specialists, and primary care physicians.
We also work with obstetricians, pediatricians, cardiologists, and others to diagnose and define genetic mechanisms involved in delayed development, drug responses, and prenatal care. Our services include a variety of standard and high-technology methodologies to assist in the screening, diagnosis, management, and follow up of patients.
Located in Shreveport, Louisiana, The Delta Pathology Group, L.L.C. has been serving the Ark-La-Tex for over 30 years.
U.S. FDA-Approved KRAS Coming Soon
Verifications are currently in progress for KRAS mutations, the only FDA-approved, biomarker directed therapy for metastatic colorectal cancer patients. The drug Erbitux has been approved for use in patients with metastatic colorectal cancer which are KRAS mutation-negative (wild-type) tumors. Both the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®, Category 2A)* and the American Society of Clinical Oncology (ASCO) recommend KRAS gene testing in colorectal cancer patients at diagnosis of metastatic disease. Our FDA approved KRAS testing should go live by the end of October 2012.